Global High-Throughput Screening Market Size to grow at a CAGR of 10.61% by 2032, Evaluates DelveInsight

According to DelveInsight's analysis, The global high-throughput screening market is anticipated to grow rapidly, driven by the increasing prevalence of chronic and infectious diseases, expanding research collaborations, and continuous product innovations by major players. Advancements in drug discovery technologies and the rising demand for precision medicine are key contributors to market growth. Furthermore, growing investments and funding aimed at accelerating drug discovery processes are expected to further boost the expansion of the high-throughput screening market throughout the forecast period (2025-2032).

DelveInsight's "High-Throughput Screening Market Insights, Competitive Landscape and Market Forecast-2032" report provides the current and forecast market outlook, forthcoming device innovation, challenges, market drivers and barriers. The report also covers the major emerging products and key High-Throughput Screening companies actively working in the market.

To know more about why North America is leading the market growth in the High-Throughput Screening market, get a snapshot of the report High-Throughput Screening Market Trends
https://www.delveinsight.com/sample-request/high-throughput-screening-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

High-Throughput Screening Overview
High-Throughput Screening (HTS) is a drug discovery technique used to rapidly test thousands of chemical compounds or biological samples for potential activity against specific biological targets. It utilizes automation, robotics, and data analysis tools to quickly identify promising drug candidates. HTS helps researchers accelerate the early stages of drug development by efficiently screening large libraries of molecules to find those with desirable therapeutic properties.

DelveInsight Analysis: The high-throughput screening market size is projected to expand at a CAGR of 10.61% throughout the forecast period from 2025 to 2032.

High-Throughput Screening Market Insights
Geographically, North America is expected to hold the largest share of the high-throughput screening market in 2024, primarily driven by the growing prevalence of chronic diseases such as cancer. Strong government support, increasing research funding, and the presence of key industry players are major factors fueling the growth of the high-throughput screening market in the region.

To read more about the latest highlights related to High-Throughput Screening, get a snapshot of the key highlights entailed in the High-Throughput Screening Insights
https://www.delveinsight.com/report-store/high-throughput-screening-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Recent Developments in the High-Throughput Screening Market Report
• In November 2023, Axxam S.p.A. and Momentum Biotechnologies joined forces to offer distinctive drug discovery solutions tailored for biotechnology and pharmaceutical clients. Under this partnership, Axxam's meticulously curated chemical diversity library, consisting of 325,000 compounds, was accessible for high-throughput screening utilizing Momentum's mass spectrometry-based functional and binding assay platforms.
• In July 2023, Illumina Inc., a US-based biotechnology company announced the launch of DRAGENTM software for the analysis of next-generation sequencing data has been unveiled. DRAGEN 4.2 builds upon its accuracy and renowned flexibility and scalability, empowering efficient workflows and the extraction of valuable insights from genomic data for the identification of genetic disease causes, drug discovery, and population genomics.
• In January 2023, Charles River Laboratories, Inc. completed the acquisition of SAMDI Tech, Inc., a prominent provider of high-quality, label-free high-throughput screening (HTS) solutions utilized in drug discovery research. By acquiring SAMDI Tech's cutting-edge, high-throughput screening technology, Charles River Laboratories is bolstering its drug discovery capabilities. This move enhanced its distinct capacity to act as an integrated partner, offering comprehensive support for early-stage drug research and development initiatives.
• Thus, owing to such developments in the market, rapid growth will be observed in the High-Throughput Screening market during the forecast period

Key Players in the High-Throughput Screening Market
Some of the key market players operating in the High-Throughput Screening market include- Agilent Technologies, Inc., Axxam S.p.A., Danaher Corporation, Bio-Rad Laboratories, Inc., Merck & Co., Inc., PerkinElmer Inc., Tecan Trading AG, Thermo Fisher Scientific Inc., Promega Corporation, Aurora Biomed Inc., Illumina, Inc., Oxford Nanopore Technologies plc, Corning Incorporated, F. Hoffmann-La Roche Ltd, Sygnature Discovery, BPS Bioscience, Inc., Revvity, Charles River Laboratories, Hamilton Company, UPM Biomedicals, and others.

Which MedTech key players in the High-Throughput Screening market are set to emerge as the trendsetter explore @ Key High-Throughput Screening Companies
https://www.delveinsight.com/sample-request/high-throughput-screening-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Analysis on the High-Throughput Screening Market Landscape
In January 2024, BD, a US-based pharmaceutical and medical technology company, announced a partnership with Hamilton, a leader in laboratory automation, to develop robotics-compatible reagent kits. This collaboration aims to enhance standardization and reduce human error in large-scale single-cell multiomics experiments, minimizing experimental bias.
Additionally, cell-based assays serve as essential tools in biomedical research and drug discovery, enabling the assessment of cytotoxicity, biological activity, biochemical pathways, and off-target effects. The widespread adoption of these assays in both primary and secondary screening is expected to drive segment growth, thereby contributing to the overall expansion of the high-throughput screening market during the forecast period.

Scope of the High-Throughput Screening Market Report
• Coverage: Global
• Study Period: 2022-2032
• High-Throughput Screening Market Segmentation By Product: Instruments, Reagents and Kits, and Software
• High-Throughput Screening Market Segmentation By Technology: Cell-Based Assays, Ultra-High-Throughput Screening, Lab-On-A-Chip Technology, Label-Free High-Throughput Screening, and Next-Generation Sequencing (NGS)
• High-Throughput Screening Market Segmentation By Application: In Vitro ADME Analysis, Drug Discovery & Development, Therapeutic Drug Monitoring, Lead Optimization, and Others
• High-Throughput Screening Market Segmentation By End-User: Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Academic and Government Institutes, and Others
• High-Throughput Screening Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of the World
• Key High-Throughput Screening Companies: Agilent Technologies, Inc., Axxam S.p.A., Danaher Corporation, Bio-Rad Laboratories, Inc., Merck & Co., Inc., PerkinElmer Inc., Tecan Trading AG, Thermo Fisher Scientific Inc., Promega Corporation, Aurora Biomed Inc., Illumina, Inc., Oxford Nanopore Technologies plc, Corning Incorporated, F. Hoffmann-La Roche Ltd, Sygnature Discovery, BPS Bioscience, Inc., Revvity, Charles River Laboratories, Hamilton Company, UPM Biomedicals, and others
• Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View

Interested in knowing how the High-Throughput Screening market will grow by 2032? Click to get a snapshot of the High-Throughput Screening Market Analysis
https://www.delveinsight.com/sample-request/high-throughput-screening-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Contact Us
Gaurav Bora
info@delveinsight.com
+14699457679
www.delveinsight.com

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.